Harrow Engages Investors at Key Conferences to Showcase Eyecare Innovations

Harrow’s Strategic Engagement at Upcoming Investor Conferences

Harrow, Inc., a leading North American eyecare pharmaceutical company, announces its participation in three significant investor conferences aimed at enhancing investor relationships and showcasing its innovative eyecare solutions. The Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, marks the beginning of this engagement, where Harrow will conduct one-on-one meetings with investors at the Sheraton New York Times Square Hotel. This format allows for in-depth discussions about the company's strategic initiatives and product pipelines, offering investors a unique opportunity to interact closely with Harrow's management team.

Following the Craig-Hallum event, Harrow will participate in the BTIG 4th Annual Ophthalmology Day on December 2, 2024. This virtual conference also emphasizes one-on-one meetings, enabling Harrow to connect with investors from the comfort of their own locations. As a company dedicated to the development and commercialization of ophthalmic pharmaceutical products, Harrow's focus during this event will be on presenting its commitment to advancing eyecare solutions and addressing the needs of eyecare professionals and patients alike. The virtual format allows for broader participation and accessibility, aligning with Harrow's mission to keep its offerings affordable and widely available.

The Piper Sandler 36th Annual Healthcare Conference, running from December 3-5, 2024, will be the final event in this series. Notably, Harrow will host a Fireside Chat on December 4 at 8:00 a.m. ET, providing a platform for deeper insights into its strategic goals and product innovations. The inclusion of an audio webcast for this chat underscores Harrow's commitment to transparency and engagement, allowing a wider audience to participate in the discussion. Investors interested in these conferences can arrange meetings through the respective firms hosting the events, further facilitating direct engagement with Harrow's leadership team.

In addition to these conferences, Harrow maintains its dedication to the eyecare industry with a robust portfolio of prescription and non-prescription products. The company's innovative approach aims to empower eyecare professionals to effectively preserve sight, making a tangible difference in the lives of millions of patients each year. For those seeking more information about Harrow and its commitment to advancing eyecare solutions, the company's website, harrow.com, serves as a valuable resource.

Through its active participation in these investor conferences, Harrow not only seeks to build stronger relationships with its investors but also aims to reinforce its position as a leader in the eyecare pharmaceutical market. By engaging in meaningful conversations about its strategic direction and product offerings, Harrow continues to emphasize its commitment to innovation and accessibility in eyecare.